- Home
- AACB vs MRVI Comparison
AACB vs MRVI Comparison
Compare AACB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACB
- MRVI
- Stock Information
- Founded
- AACB 2024
- MRVI 2014
- Country
- AACB United States
- MRVI United States
- Employees
- AACB N/A
- MRVI N/A
- Industry
- AACB
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- AACB
- MRVI Health Care
- Exchange
- AACB Nasdaq
- MRVI Nasdaq
- Market Cap
- AACB 298.1M
- MRVI 312.4M
- IPO Year
- AACB 2025
- MRVI 2020
- Fundamental
- Price
- AACB $10.14
- MRVI $2.08
- Analyst Decision
- AACB
- MRVI Hold
- Analyst Count
- AACB 0
- MRVI 10
- Target Price
- AACB N/A
- MRVI $6.84
- AVG Volume (30 Days)
- AACB 11.5K
- MRVI 1.5M
- Earning Date
- AACB 01-01-0001
- MRVI 08-06-2025
- Dividend Yield
- AACB N/A
- MRVI N/A
- EPS Growth
- AACB N/A
- MRVI N/A
- EPS
- AACB N/A
- MRVI N/A
- Revenue
- AACB N/A
- MRVI $241,856,000.00
- Revenue This Year
- AACB N/A
- MRVI N/A
- Revenue Next Year
- AACB N/A
- MRVI $10.73
- P/E Ratio
- AACB N/A
- MRVI N/A
- Revenue Growth
- AACB N/A
- MRVI N/A
- 52 Week Low
- AACB $10.00
- MRVI $1.67
- 52 Week High
- AACB $11.35
- MRVI $10.03
- Technical
- Relative Strength Index (RSI)
- AACB N/A
- MRVI 46.40
- Support Level
- AACB N/A
- MRVI $2.00
- Resistance Level
- AACB N/A
- MRVI $2.44
- Average True Range (ATR)
- AACB 0.00
- MRVI 0.15
- MACD
- AACB 0.00
- MRVI -0.03
- Stochastic Oscillator
- AACB 0.00
- MRVI 20.45
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.